Ignite Creation Date:
2025-12-24 @ 6:31 PM
Ignite Modification Date:
2025-12-30 @ 3:13 PM
Study NCT ID:
NCT00955357
Status:
COMPLETED
Last Update Posted:
2018-07-17
First Post:
2009-08-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Germany', 'Hungary']}, 'conditionBrowseModule': {'meshes': [{'id': 'D004828', 'term': 'Epilepsies, Partial'}, {'id': 'D012640', 'term': 'Seizures'}], 'ancestors': [{'id': 'D004827', 'term': 'Epilepsy'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000078334', 'term': 'Lacosamide'}, {'id': 'C476828', 'term': '2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-'}], 'ancestors': [{'id': 'D000081', 'term': 'Acetamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000085', 'term': 'Acetates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '+1 877 822 9493', 'title': 'UCB Clinical Trial Call Center', 'organization': 'UCB'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'This study was intended to assess the efficacy outcomes in the First Add-On Group and the Later Add-On Group individually relative to historical data. Comparisons between the 2 groups should not be attempted and conclusions should not be drawn.'}}, 'adverseEventsModule': {'timeFrame': 'Treatment Emergent Adverse Events were collected from Screening (Week -1) until the end of the study ( up to Week 33).', 'description': 'Treatment Emergent Adverse Events started on/after the date of first dose and within 30 days of the date of last dose.', 'eventGroups': [{'id': 'EG000', 'title': 'First Add-on', 'description': 'Lacosamide added to first adequate monotherapy (no history of AED polytherapy) and epilepsy diagnosis \\< or = 24 months at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks):\n\nWeek 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks):\n\n200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks):\n\n50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week', 'otherNumAtRisk': 96, 'otherNumAffected': 53, 'seriousNumAtRisk': 96, 'seriousNumAffected': 8}, {'id': 'EG001', 'title': 'Later Add-on', 'description': 'Lacosamide added to 1 to 3 AEDs (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis \\> or = 5 years at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks):\n\nWeek 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks):\n\n200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks):\n\n50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week', 'otherNumAtRisk': 360, 'otherNumAffected': 212, 'seriousNumAtRisk': 360, 'seriousNumAffected': 19}], 'otherEvents': [{'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 11, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 22, 'numAffected': 22}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Vision blurred', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 28, 'numAffected': 24}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Diplopia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 17, 'numAffected': 17}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 27, 'numAffected': 24}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 37, 'numAffected': 30}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 159, 'numAffected': 119}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 65, 'numAffected': 54}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 19, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 57, 'numAffected': 41}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 23, 'numAffected': 22}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}], 'seriousEvents': [{'term': 'Agranulocytosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Diplopia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Chest discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Tooth abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Arthropod bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Femoral neck fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Hip fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Humerus fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Joint dislocation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Subdural haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Electrocardiogram ST segment elevation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Hypochloraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Convulsion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Complex partial seizures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Coordination abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Dysarthria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Dyskinesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Grand mal convulsion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Lacunar infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Partial seizures with secondary generalisation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Panic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Suicide attempt', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}, {'term': 'Abortion induced', 'stats': [{'groupId': 'EG000', 'numAtRisk': 96, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 360, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'The Proportion of Subjects Who Achieved "Seizure-free Status" During the First 12 Weeks of the Maintenance Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '261', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'First Add-on', 'description': 'Lacosamide added to first adequate monotherapy (no history of AED polytherapy) and epilepsy diagnosis \\< or = 24 months at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks): Week 1 - 50 mg tablet twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks): 200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks): 50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week'}, {'id': 'OG001', 'title': 'Later Add-on', 'description': 'Lacosamide added to 1 to 3 AEDs (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis \\> or = 5 years at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks): Week 1 - 50 mg tablet twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks): 200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks): 50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week'}], 'classes': [{'categories': [{'measurements': [{'value': '37.5', 'groupId': 'OG000'}, {'value': '14.9', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Week 7 (end of Week 6) to end of Week 18', 'description': 'A subject will be considered seizure-free if the subject completes the first 12 weeks of the Maintenance Phase, reports zero seizures, and has no seizure data missing for any day during the period of time.\n\nThis study was intended to assess the efficacy outcomes in the First Add-On Group and the Later Add-On Group individually relative to historical data. Comparisons between the 2 groups should not be attempted and conclusions should not be drawn.', 'unitOfMeasure': 'percentage of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The Analysis Population refers to the Completer Set (CS) which includes all subjects who were enrolled, received at least one dose of Lacosamide and completed the first 12 weeks of the Maintenance Phase.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'First Add-on', 'description': 'Lacosamide added to first adequate monotherapy (no history of Anti-Epileptic Drug \\[AED\\] polytherapy) and epilepsy diagnosis \\< or = 24 months at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks): Week 1 - 50 mg tablet twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks): 200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks): 50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week'}, {'id': 'FG001', 'title': 'Later Add-on', 'description': 'Lacosamide added to 1 to 3 Anti-Epileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis \\> or = 5 years at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks): Week 1 - 50 mg tablet twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks): 200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks): 50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week'}], 'periods': [{'title': 'Titration Phase', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '96'}, {'groupId': 'FG001', 'numSubjects': '360'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '80'}, {'groupId': 'FG001', 'numSubjects': '294'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '66'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '46'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '7'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': 'Prohibited Antiepileptic Drug change', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Study medication not tolerated', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Non compliance to study procedures', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}, {'title': 'Maintenance Phase', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '80'}, {'groupId': 'FG001', 'numSubjects': '294'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '68'}, {'groupId': 'FG001', 'numSubjects': '249'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '45'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '23'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '7'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Patient moving out of area', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Non compliance to study procedures', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'An estimated 656 subjects were to be enrolled in the study at approximately 130 sites in the US, Europe, and the rest of the world.', 'preAssignmentDetails': 'Overall 461 subjects were enrolled. The Participant Flow refers to the Safety Set (SS) which was defined as all enrolled subjects who took at least 1 dose of Lacosamide. Reasons for discontinuation were only calculated for the SS. 456 subjects were included in the Safety Set.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '96', 'groupId': 'BG000'}, {'value': '360', 'groupId': 'BG001'}, {'value': '456', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'First Add-on', 'description': 'Lacosamide added to first adequate monotherapy (no history of AED polytherapy) and epilepsy diagnosis \\< or = 24 months at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks): Week 1 - 50 mg tablet twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks): 200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks): 50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week'}, {'id': 'BG001', 'title': 'Later-Add-on', 'description': 'Lacosamide added to 1 to 3 AEDs (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis \\> or = 5 years at Screening.\n\nLacosamide: oral tablet\n\nSubjects Titration Phase (6 Weeks): Week 1 - 50 mg tablet twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks): 200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks): 50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '37.5', 'groupId': 'BG000', 'lowerLimit': '18.0', 'upperLimit': '82.0'}, {'value': '38.0', 'groupId': 'BG001', 'lowerLimit': '16.0', 'upperLimit': '74.0'}, {'value': '38.0', 'groupId': 'BG002', 'lowerLimit': '16.0', 'upperLimit': '82.0'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '82', 'groupId': 'BG000'}, {'value': '349', 'groupId': 'BG001'}, {'value': '431', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '14', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '53', 'groupId': 'BG000'}, {'value': '180', 'groupId': 'BG001'}, {'value': '233', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '180', 'groupId': 'BG001'}, {'value': '223', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '79', 'groupId': 'BG000'}, {'value': '278', 'groupId': 'BG001'}, {'value': '357', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '45', 'groupId': 'BG001'}, {'value': '50', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '24', 'groupId': 'BG000'}, {'value': '99', 'groupId': 'BG001'}, {'value': '123', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '72', 'groupId': 'BG000'}, {'value': '261', 'groupId': 'BG001'}, {'value': '333', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Weight', 'classes': [{'categories': [{'measurements': [{'value': '71.8', 'groupId': 'BG000', 'lowerLimit': '42.0', 'upperLimit': '132.9'}, {'value': '73.0', 'groupId': 'BG001', 'lowerLimit': '41.9', 'upperLimit': '147.4'}, {'value': '73.0', 'groupId': 'BG002', 'lowerLimit': '41.9', 'upperLimit': '147.4'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'kilogram', 'dispersionType': 'FULL_RANGE'}, {'title': 'Height', 'classes': [{'categories': [{'measurements': [{'value': '166.5', 'groupId': 'BG000', 'lowerLimit': '149.0', 'upperLimit': '186.0'}, {'value': '167.6', 'groupId': 'BG001', 'lowerLimit': '140.0', 'upperLimit': '197.0'}, {'value': '167.6', 'groupId': 'BG002', 'lowerLimit': '140.0', 'upperLimit': '197.0'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'centimeter', 'dispersionType': 'FULL_RANGE'}, {'title': 'BMI', 'classes': [{'categories': [{'measurements': [{'value': '25.3', 'groupId': 'BG000', 'lowerLimit': '14.5', 'upperLimit': '42.5'}, {'value': '25.5', 'groupId': 'BG001', 'lowerLimit': '17.3', 'upperLimit': '53.9'}, {'value': '25.4', 'groupId': 'BG002', 'lowerLimit': '14.5', 'upperLimit': '53.9'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'kilogram per m^2', 'dispersionType': 'FULL_RANGE'}], 'populationDescription': 'The Baseline Analysis Population refers to the Safety Set (SS) which includes all enrolled subjects who took at least one dose of study medication. 5 subjects at one site were excluded from the Safety Set due to significant study conduct deficiencies.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 461}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2009-08'}, 'expandedAccessInfo': {'nctId': 'NCT03559673', 'statusForNctId': 'NO_LONGER_AVAILABLE', 'hasExpandedAccess': True}, 'statusVerifiedDate': '2017-07', 'completionDateStruct': {'date': '2013-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-06-20', 'studyFirstSubmitDate': '2009-08-06', 'resultsFirstSubmitDate': '2014-03-28', 'studyFirstSubmitQcDate': '2009-08-07', 'lastUpdatePostDateStruct': {'date': '2018-07-17', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2014-03-28', 'studyFirstPostDateStruct': {'date': '2009-08-10', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2014-05-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The Proportion of Subjects Who Achieved "Seizure-free Status" During the First 12 Weeks of the Maintenance Phase', 'timeFrame': 'From Week 7 (end of Week 6) to end of Week 18', 'description': 'A subject will be considered seizure-free if the subject completes the first 12 weeks of the Maintenance Phase, reports zero seizures, and has no seizure data missing for any day during the period of time.\n\nThis study was intended to assess the efficacy outcomes in the First Add-On Group and the Later Add-On Group individually relative to historical data. Comparisons between the 2 groups should not be attempted and conclusions should not be drawn.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Epilepsy Treatment', 'Anti-epileptic drugs', 'Seizures', 'Vimpat'], 'conditions': ['Partial Epilepsies']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm', 'label': 'FDA Safety Alerts and Recalls'}]}, 'descriptionModule': {'briefSummary': 'To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects who have received treatment with at least 2 AEDs.', 'detailedDescription': 'The study consisted of 3 Periods: Period 1: a 1-week Screening Phase, Period 2: a 30-week Treatment Phase (consisting of a 6-week Titration Phase and a 24-week Maintenance Phase), and Period 3: a 3-week Taper/Safety Follow-Up Phase.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '17 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nGroup 1:\n\n* Subject has a diagnosis of epilepsy with simple partial seizures (motor component) and/or complex partial seizures with or without secondary generalization\n* Currently taking adequate monotherapy (defined as a single Antiepileptic Drug (AED) for at least 28 days prior to Screening) and has no history of AED polytherapy. Prior use of rescue medication (short-term intermittent use) is acceptable\n* Epilepsy diagnosis should be ≤24 months at the time of the Screening Visit\n* The minimum allowed seizure frequency at any time during the 12 weeks prior to the Screening Visit is ≥3 partial-onset seizures\n\nGroup 2:\n\n* Subject has a diagnosis of epilepsy with simple partial seizures (motor component) and/or complex partial seizures with or without secondary generalization\n* Currently taking 1 to 3 AEDs, and has tried at least 2 prior AED treatment regimens (concurrently or sequentially)\n* Epilepsy diagnosis should be ≥5 years at the time of the Screening Visit\n* The minimum allowed seizure frequency during the 12 weeks prior to the Screening Visit is ≥1 partial-onset seizure per 28 days\n\nExclusion Criteria:\n\n* Previous use of Lacosamide\n* History of seizure disorder characterized primarily by isolated auras\n* History of primary generalized seizures\n* History of status epilepticus within last 12-months\n* History of cluster seizures during the 12 week period prior to Visit 1\n* Nonepileptic events, including pseudoseizures that could be confused with seizure\n* Lifetime history of suicide attempt or suicidal ideation in the past 6 months\n* Hypersensitivity to any component of Lacosamide\n* History of drug or alcohol abuse\n* History of an acute or subacutely progressive Central Nervous System (CNS) disease\n* Undergone cranial surgery within the last year prior to study entry\n* Concomitant treatment of Felbamate or previous Felbamate therapy within the last 6 months\n* Prior or concomitant Vigabatrin use'}, 'identificationModule': {'nctId': 'NCT00955357', 'briefTitle': 'Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures', 'organization': {'class': 'INDUSTRY', 'fullName': 'UCB Pharma'}, 'officialTitle': 'An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures', 'orgStudyIdInfo': {'id': 'SP0954'}, 'secondaryIdInfos': [{'id': '2009-011181-28', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'First Add-on', 'description': 'Lacosamide added to first adequate monotherapy (no history of Antiepileptic Drug \\[AED\\] polytherapy) and epilepsy diagnosis \\< or = 24 months at Screening.', 'interventionNames': ['Drug: Lacosamide']}, {'type': 'EXPERIMENTAL', 'label': 'Later Add-on', 'description': 'Lacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis \\> or = 5 years at Screening.', 'interventionNames': ['Drug: Lacosamide']}], 'interventions': [{'name': 'Lacosamide', 'type': 'DRUG', 'otherNames': ['SPM927', 'Harkoseride', 'Vimpat'], 'description': 'Oral Lacosamide:\n\nSubjects Titration Phase (6 Weeks):\n\nWeek 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid\n\nMaintenance Phase (24 Weeks):\n\n200 mg tablet bid OR 150 mg tablet bid\n\nTaper Phase (1 - 3 Weeks):\n\n50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week', 'armGroupLabels': ['First Add-on', 'Later Add-on']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Irvine', 'state': 'California', 'country': 'United States', 'facility': '103', 'geoPoint': {'lat': 33.66946, 'lon': -117.82311}}, {'city': 'Rancho Mirage', 'state': 'California', 'country': 'United States', 'facility': '123', 'geoPoint': {'lat': 33.73974, 'lon': -116.41279}}, {'city': 'Clearwater', 'state': 'Florida', 'country': 'United States', 'facility': '156', 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'city': 'Destin', 'state': 'Florida', 'country': 'United States', 'facility': '157', 'geoPoint': {'lat': 30.39353, 'lon': -86.49578}}, {'city': 'Hollywood', 'state': 'Florida', 'country': 'United States', 'facility': '140', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'city': 'Ocala', 'state': 'Florida', 'country': 'United States', 'facility': '161', 'geoPoint': {'lat': 29.1872, 'lon': -82.14009}}, {'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': '108', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': '112', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'city': 'Augusta', 'state': 'Georgia', 'country': 'United States', 'facility': '124', 'geoPoint': {'lat': 33.47097, 'lon': -81.97484}}, {'city': 'Macon', 'state': 'Georgia', 'country': 'United States', 'facility': '115', 'geoPoint': {'lat': 32.84069, 'lon': -83.6324}}, {'city': 'Rome', 'state': 'Georgia', 'country': 'United States', 'facility': '118', 'geoPoint': {'lat': 34.25704, 'lon': -85.16467}}, {'city': 'Flossmoor', 'state': 'Illinois', 'country': 'United States', 'facility': '128', 'geoPoint': {'lat': 41.54281, 'lon': -87.68477}}, {'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': '130', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'city': 'Bowling Green', 'state': 'Kentucky', 'country': 'United States', 'facility': '102', 'geoPoint': {'lat': 36.99032, 'lon': -86.4436}}, {'city': 'Paducah', 'state': 'Kentucky', 'country': 'United States', 'facility': '117', 'geoPoint': {'lat': 37.08339, 'lon': -88.60005}}, {'city': 'Houma', 'state': 'Louisiana', 'country': 'United States', 'facility': '107', 'geoPoint': {'lat': 29.59577, 'lon': -90.71953}}, {'city': 'Ruston', 'state': 'Louisiana', 'country': 'United States', 'facility': '145', 'geoPoint': {'lat': 32.52321, 'lon': -92.63793}}, {'city': 'Annapolis', 'state': 'Maryland', 'country': 'United States', 'facility': '101', 'geoPoint': {'lat': 38.97859, 'lon': -76.49184}}, {'city': 'Waldorf', 'state': 'Maryland', 'country': 'United States', 'facility': '162', 'geoPoint': {'lat': 38.62456, 'lon': -76.93914}}, {'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': '153', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'city': 'Pittsfield', 'state': 'Massachusetts', 'country': 'United States', 'facility': '136', 'geoPoint': {'lat': 42.45008, 'lon': -73.24538}}, {'city': 'Springfield', 'state': 'Massachusetts', 'country': 'United States', 'facility': '144', 'geoPoint': {'lat': 42.10148, 'lon': -72.58981}}, {'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'facility': '151', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'city': 'Paterson', 'state': 'New Jersey', 'country': 'United States', 'facility': '114', 'geoPoint': {'lat': 40.91677, 'lon': -74.17181}}, {'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': '109', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': '133', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'city': 'West Seneca', 'state': 'New York', 'country': 'United States', 'facility': '127', 'geoPoint': {'lat': 42.85006, 'lon': -78.79975}}, {'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': '158', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'city': 'Bismarck', 'state': 'North Dakota', 'country': 'United States', 'facility': '139', 'geoPoint': {'lat': 46.80833, 'lon': -100.78374}}, {'city': 'Akron', 'state': 'Ohio', 'country': 'United States', 'facility': '134', 'geoPoint': {'lat': 41.08144, 'lon': -81.51901}}, {'city': 'Canton', 'state': 'Ohio', 'country': 'United States', 'facility': '150', 'geoPoint': {'lat': 40.79895, 'lon': -81.37845}}, {'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': '141', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'city': 'Indiana', 'state': 'Pennsylvania', 'country': 'United States', 'facility': '121', 'geoPoint': {'lat': 40.62146, 'lon': -79.15253}}, {'city': 'Columbia', 'state': 'South Carolina', 'country': 'United States', 'facility': '120', 'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}, {'city': 'Orangeburg', 'state': 'South Carolina', 'country': 'United States', 'facility': '149', 'geoPoint': {'lat': 33.49182, 'lon': -80.85565}}, {'city': 'Spartanburg', 'state': 'South Carolina', 'country': 'United States', 'facility': '152', 'geoPoint': {'lat': 34.94957, 'lon': -81.93205}}, {'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': '148', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': '154', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'city': 'Tomball', 'state': 'Texas', 'country': 'United States', 'facility': '146', 'geoPoint': {'lat': 30.09716, 'lon': -95.61605}}, {'city': 'Fredericksburg', 'state': 'Virginia', 'country': 'United States', 'facility': '119', 'geoPoint': {'lat': 38.30318, 'lon': -77.46054}}, {'city': 'Vienna', 'country': 'Austria', 'facility': '503', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'city': 'Blagoevrad', 'country': 'Bulgaria', 'facility': '703'}, {'city': 'Pleven', 'country': 'Bulgaria', 'facility': '706', 'geoPoint': {'lat': 43.41791, 'lon': 24.61666}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '700', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '702', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '704', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '705', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '707', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': '708', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Varna', 'country': 'Bulgaria', 'facility': '701', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'city': 'Hradec Králové', 'country': 'Czechia', 'facility': '736', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'city': 'Litoměřice', 'country': 'Czechia', 'facility': '735', 'geoPoint': {'lat': 50.53348, 'lon': 14.1318}}, {'city': 'Ostrava', 'country': 'Czechia', 'facility': '733', 'geoPoint': {'lat': 49.83465, 'lon': 18.28204}}, {'city': 'Ostrava-Hrabuvka', 'country': 'Czechia', 'facility': '732'}, {'city': 'Prague', 'country': 'Czechia', 'facility': '737', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Trutnov', 'country': 'Czechia', 'facility': '734', 'geoPoint': {'lat': 50.56101, 'lon': 15.9127}}, {'city': 'Aarhus', 'country': 'Denmark', 'facility': '930', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'city': 'Helsinki', 'country': 'Finland', 'facility': '400', 'geoPoint': {'lat': 60.16952, 'lon': 24.93545}}, {'city': 'Oulu', 'country': 'Finland', 'facility': '402', 'geoPoint': {'lat': 65.01236, 'lon': 25.46816}}, {'city': 'Tampere', 'country': 'Finland', 'facility': '401', 'geoPoint': {'lat': 61.49911, 'lon': 23.78712}}, {'city': 'Strasbourg', 'country': 'France', 'facility': '610', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'city': 'Toulon', 'country': 'France', 'facility': '611', 'geoPoint': {'lat': 43.12442, 'lon': 5.92836}}, {'city': 'Athens', 'country': 'Greece', 'facility': '521', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'city': 'Thessaloniki', 'country': 'Greece', 'facility': '520', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'city': 'Faenza', 'country': 'Italy', 'facility': '552', 'geoPoint': {'lat': 44.29007, 'lon': 11.87948}}, {'city': 'Gallarate', 'country': 'Italy', 'facility': '546', 'geoPoint': {'lat': 45.66019, 'lon': 8.79164}}, {'city': 'Napoli', 'country': 'Italy', 'facility': '541', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'city': 'Pietra Ligure', 'country': 'Italy', 'facility': '559', 'geoPoint': {'lat': 44.1492, 'lon': 8.28206}}, {'city': 'Prato', 'country': 'Italy', 'facility': '557', 'geoPoint': {'lat': 43.8805, 'lon': 11.09699}}, {'city': 'Roma', 'country': 'Italy', 'facility': '540', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Roma', 'country': 'Italy', 'facility': '549', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Taranto', 'country': 'Italy', 'facility': '542', 'geoPoint': {'lat': 40.46438, 'lon': 17.24707}}, {'city': 'Torino', 'country': 'Italy', 'facility': '547', 'geoPoint': {'lat': 44.88856, 'lon': 11.99138}}, {'city': 'Trieste', 'country': 'Italy', 'facility': '551', 'geoPoint': {'lat': 45.64953, 'lon': 13.77678}}, {'city': 'Aguascalientes', 'country': 'Mexico', 'facility': '180', 'geoPoint': {'lat': 21.88262, 'lon': -102.2843}}, {'city': 'Chihuahua City', 'country': 'Mexico', 'facility': '183', 'geoPoint': {'lat': 28.63528, 'lon': -106.08889}}, {'city': 'Chihuahua City', 'country': 'Mexico', 'facility': '185', 'geoPoint': {'lat': 28.63528, 'lon': -106.08889}}, {'city': 'Ciudad Juárez', 'country': 'Mexico', 'facility': '184', 'geoPoint': {'lat': 31.72024, 'lon': -106.46084}}, {'city': 'Guadalajara', 'country': 'Mexico', 'facility': '189', 'geoPoint': {'lat': 20.67738, 'lon': -103.34749}}, {'city': 'Mexico City', 'country': 'Mexico', 'facility': '181', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'city': 'Mexico City', 'country': 'Mexico', 'facility': '193', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'city': 'Mexico City', 'country': 'Mexico', 'facility': '195', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'city': 'Monterrey', 'country': 'Mexico', 'facility': '186', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'city': 'Monterrey', 'country': 'Mexico', 'facility': '187', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'city': 'Monterrey', 'country': 'Mexico', 'facility': '188', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'city': 'Polanco', 'country': 'Mexico', 'facility': '182', 'geoPoint': {'lat': 19.43332, 'lon': -99.19919}}, {'city': 'Bucharest', 'country': 'Romania', 'facility': '815', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'city': 'Cluj-Napoca', 'country': 'Romania', 'facility': '810', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'city': 'Oradea', 'country': 'Romania', 'facility': '814', 'geoPoint': {'lat': 47.0458, 'lon': 21.91833}}, {'city': 'Târgu Mureş', 'country': 'Romania', 'facility': '813', 'geoPoint': {'lat': 46.54245, 'lon': 24.55747}}, {'city': "Kazan'", 'country': 'Russia', 'facility': '830', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'city': "Kazan'", 'country': 'Russia', 'facility': '831', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'city': 'Moscow', 'country': 'Russia', 'facility': '834', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Novosibirsk', 'country': 'Russia', 'facility': '833', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'city': 'Terrassa', 'state': 'Barcelona', 'country': 'Spain', 'facility': '598', 'geoPoint': {'lat': 41.56667, 'lon': 2.01667}}, {'city': 'Almería', 'country': 'Spain', 'facility': '592', 'geoPoint': {'lat': 36.83814, 'lon': -2.45974}}, {'city': 'Bajo Sevilla', 'country': 'Spain', 'facility': '597'}, {'city': 'Barcelona', 'country': 'Spain', 'facility': '590', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': '596', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'city': 'Valencia', 'country': 'Spain', 'facility': '594', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Valladolid', 'country': 'Spain', 'facility': '599', 'geoPoint': {'lat': 41.65541, 'lon': -4.72353}}, {'city': 'Lausanne', 'country': 'Switzerland', 'facility': '892', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'city': 'Adana', 'country': 'Turkey (Türkiye)', 'facility': '713', 'geoPoint': {'lat': 36.98615, 'lon': 35.32531}}, {'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': '714', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'city': 'Eskişehir', 'country': 'Turkey (Türkiye)', 'facility': '710', 'geoPoint': {'lat': 39.77667, 'lon': 30.52056}}, {'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': '711', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': '719', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': '717', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'city': 'Trabzon', 'country': 'Turkey (Türkiye)', 'facility': '718', 'geoPoint': {'lat': 41.005, 'lon': 39.72694}}], 'overallOfficials': [{'name': 'UCB Clinical Trial Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': '+1 877 822 9493 (UCB)'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'UCB Pharma', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}